5thN Financial
  • Home
  • ETF
  • Software
  • Continuing Education
  • Active Research
  • Who
  • SEC Check
  • BrokerCheck

Active Research

Expanded Portfolio Theory, asset modeling, and computational portfolio research.

Active research for practical portfolio construction

5thN Financial’s research supports actively managed ETF construction through Expanded Portfolio Theory, asset modeling, constraints, and systematic backtesting.

Research framework

Expanded Portfolio Theory and HiFuPi

EPT

Expanded Portfolio Theory

EPT is a flexible allocation framework for portfolio problems that may include realistic constraints, turnover limits, nonlinear positions, and operating rules.

HFP

HiFuPi asset model

HiFuPi provides the asset-model inputs used by the EPT allocation process for forward-looking analysis and backtesting.

MPT assumptions and EPT flexibility

MPT contains an embedded set of assumptions. When those same assumptions are imposed on EPT, the resulting solution is the same as MPT. In that sense, MPT is a special case within the broader EPT framework.

EPT does not require those assumptions to be fixed in advance. It can therefore address a wider range of portfolio situations, including alternative constraints, turnover rules, operational requirements, tax considerations, and objectives that do not fit neatly inside classic MPT.

Practical implication

EPT does not reject MPT. It preserves MPT as one valid case while providing a broader computational language for portfolio design, testing, and implementation.

Research-to-operation pipeline

1. Define the universe. Select eligible securities and required data.

2. Generate inputs. Build return, risk, liquidity, or signal estimates.

3. Apply EPT constraints. Add holdings, turnover, bounds, and operating rules.

4. Backtest and verify. Evaluate allocations, returns, drawdowns, and implementation effects.

5. Deliver outputs. Produce holding files, reports, graphics, and audit trails.

 

5thN Financial — Arkansas Registered Investment Advisor — CRD 286020
CEO Robert Fithen, PhD — CRD 6753415
Review all pages for current compliance language before publishing.